Digital Evidence Base

Trusted Knowledge for Informed Decisions

Filters
SDGs
Priority Areas
Research Outcomes
Document Type
Year
4019 results found
Show:
Rapid assessment of the demand and supply of tobacco dependence pharmacotherapy in Uganda
Jones R, Williams S, Kirenga B J, Nyakoojo G, Muhofa A
2016

Tobacco dependence pharmacotherapy (TDP) plays a major role in smoking cessation. We conducted a rapid assessment of current smoking, availability of TDP and the willingness to quit and to pay …

Abstract
Valuing the work of unpaid community health workers and exploring the incentives to volunteering in rural Africa
Vassall A, inSCALE Study Grp, Kasteng F, Kallander K, Settumba S
2016
DOI: 10.1093/heapol/czv042

Community health worker (CHW) programmes are currently being scaled-up in sub-Saharan Africa to improve access to healthcare. CHWs are often volunteers; from an economic perspective, this raises considerations whether reliance …

Abstract
Characterising antibody avidity in individuals of varied Mycobacterium tuberculosis infection status using surface plasmon resonance
Bagaya Bernard S., Kimuda Simon G., Biraro Irene Andia, Raynes John G., Cose Stephen
2018

MEDLINE Abstract: There is increasing evidence supporting a role for antibodies in protection against tuberculosis (TB), with functional antibodies being described in the latent state of TB infection. Antibody avidity …

Abstract
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Giugliano Robert P., Pedersen Terje R., Saver Jeffrey L., Sever Peter S., Keech Anthony C., Bohula Erin A., Murphy Sabina A., Wasserman Scott M., Honarpour Narimon, Wang Huei, Lira Pineda Armando, Sabatine Marc S.
2020
DOI: 10.1161/STROKEAHA.119.027759

Background and Purpose- The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5-1.2) mmol/L and significantly reduced major vascular events …

Abstract
EQUINET Policy Brief Number 27: Constitutional provisions for the right to health in east and southern Africa
EQUINET and CEHURD
2012

The extent to which health rights are neglected or promoted is a major factor in thepromotion of health equity in Africa. Central to this is the incorporation of the right …

Abstract
Apabetalone downregulates fibrotic, inflammatory and calcific processes in renal mesangial cells which may contribute to reduced cardiac events observed in ckd patients
Gilham D., Fu L., Rakai B., Wasiak S., Tsujikawa L., Halliday C., Sarsons C., Stotz S., Jahagirdar R., Johansson J., Sweeney M., Wong N., Kalantar-Zadeh K., Kulikowski E.
2021
DOI: 10.1093/ndt/gfab078.008

BACKGROUND AND AIMS: Major adverse cardiac events (MACE) remain a leading cause of mortality in chronic kidney disease (CKD). Apabetalone is an orally available inhibitor of bromodomain & extraterminal (BET) …

Abstract
AI Research Assistant
AI-powered research assistance. Uses the Digital Evidence Base as the Knowledge source.